depot medroxyprogesterone acetate

ApprovedSmall molecule

depot medroxyprogesterone acetate is one of 141 small molecule programs targeting Contraception. It is currently in Approved.

Indications

Total Trials

Active Trials

140

Competitors

Pipeline

Status by Indication[3][1]

Indication

ContraceptionActive, not recruiting

Ovarian CystActive, not recruiting

HysterectomyActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

EndometriosisActive, not recruiting

ContraceptionPreclinical

Active, not recruiting

Ovarian CystPhase 1/Phase 2

Active, not recruiting

HysterectomyPhase 2

Active, not recruiting

Sickle Cell DiseaseApproved

Active, not recruiting

EndometriosisApproved

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Adakveo

Novartis

Phase 3

7 2

Exjade

Novartis

Phase 3

4 3

Brilinta

AstraZeneca

Phase 3

3 4

Campath

GGenzyme, a Sanofi Company

Phase 3

12 5

Ritalin

Novartis

Phase 3

2 6

Cysteine Hydrochloride

Novartis

Phase 3

2 7

Eliquis

Bristol-Myers Squibb

Phase 3

1 8

Oxbryta

GGlobal Blood Therapeutics

Phase 3

5 9

depot medroxyprogesterone acetate

AbbVie

Approved

1 10

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Sickle Cell Disease

NCT06665997

Clinical

Trials by Indication[1]

Contraception2 trials

The Female Sexual Functions With Progestogen-only Contraception

Completed·—··NCT02579590·444 enrolled

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

Completed·LLisa Haddad·Phase 4·NCT02357368·59 enrolled

Endometriosis2 trials

Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis

Completed· AbbVie logo

AbbVie·Phase 2·NCT00437658·252 enrolled

Efficacy of Injectable Contraceptive and Oral Contraceptive Administered After Surgical Treatment of Endometriosis With Pain

Completed·PPrince of Songkla University·Phase 4·NCT01056042·112 enrolled

Women1 trial

Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women

Completed·UUniversity of Sao Paulo·N/A·NCT00828542·40 enrolled

Immunity1 trial

Contraceptive Hormones, Immunity, and Microbiome Evaluation

Completed·EEmory University··NCT03660046·155 enrolled

Progesterone1 trial

Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects

Completed·NNationwide Children's Hospital·Phase 3·NCT01461824·34 enrolled

7 more indications

Sickle Cell Disease1 trial

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

Recruiting·UUniversity of Pennsylvania·Phase 4·NCT06665997·65 enrolled

Ovarian cyst1 trial

Effect of Pre-operative Depo Medroxyprogesterone Acetate on Serum Anti-mullerian Hormone Level After Laparoscopic Ovarian Cystectomy of Endometriomas

Completed·MMahidol University·Phase 1/2·NCT01791413·40 enrolled

Effectiveness1 trial

Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients

Completed·—·Phase 2·NCT02894151·50 enrolled

Breastfeeding1 trial

Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression

Completed·BBeatrice Chen·Phase 4·NCT01463202·184 enrolled

Hysterectomy1 trial

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

Unknown status·WWomen and Infants Hospital of Rhode Island·Phase 2·NCT02335203·76 enrolled

Interaction1 trial

PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT02412436·62 enrolled

Unspecified1 trial

Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood

Completed·PPlanned Parenthood Federation of America·Phase 4·NCT02509767·401 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for depot medroxyprogesterone acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — depot medroxyprogesterone acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for depot medroxyprogesterone acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

depot medroxyprogesterone acetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Contraception2 trials

Endometriosis2 trials

Women1 trial

Immunity1 trial

Progesterone1 trial

Sickle Cell Disease1 trial

Ovarian cyst1 trial

Effectiveness1 trial

Breastfeeding1 trial

Hysterectomy1 trial

Interaction1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News